Molnupiravir-d7

Molnupiravir-d7 is the deuterium labeled Molnupiravir. Molnupiravir (EIDD-2801) is an orally bioavailable prodrug of the ribonucleoside analog EIDD-1931. Molnupiravir has broad spectrum antiviral activity against influenza virus and multiple coronaviruses, such as SARS-CoV-2, MERS-CoV, SARS-CoV. Molnupiravir has the potential for the research of COVID-19, and seasonal and pandemic influenza[1][2].

Product Specifications

Product Name Alternative

EIDD-2801-d7; MK-4482-d7

UNSPSC

12352005

Target

Influenza Virus; SARS-CoV

Type

Isotope-Labeled Compounds

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Inflammation/Immunology

Purity

99.86

Solubility

10 mM in DMSO|DMSO : 50mg/mL (ultrasonic) |H2O : 12.5mg/mL (ultrasonic)

Smiles

O=C(N([C@@]1([H])[C@H](O)[C@H](O)[C@@]([H])(COC(C(C([2H])([2H])[2H])([2H])C([2H])([2H])[2H])=O)O1)C=C2)NC2=NO

Molecular Formula

C13H12D7N3O7

Molecular Weight

336.35

References & Citations

[1]Sheahan TP, et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med. 2020 Apr 6. pii: eabb5883. |[2]Toots M, et al. Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci Transl Med. 2019 Oct 23;11 (515) . pii: eaax5866.|[3]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.